Business Description
Clearside Biomedical Inc
NAICS : 325412
SIC : 2834
ISIN : US1850632035
Total Employee Number:
32Description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.25 | |||||
Equity-to-Asset | -4.63 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -48.28 | |||||
Beneish M-Score | -7.82 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -64.3 | |||||
3-Year FCF Growth Rate | -24.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 132.17 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.26 | |||||
9-Day RSI | 64.22 | |||||
14-Day RSI | 56.52 | |||||
3-1 Month Momentum % | -60 | |||||
6-1 Month Momentum % | -84 | |||||
12-1 Month Momentum % | -98.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.98 | |||||
Quick Ratio | 2.98 | |||||
Cash Ratio | 2.46 | |||||
Days Sales Outstanding | 85.85 | |||||
Days Payable | 1407.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -83.37 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.07 | |||||
Operating Margin % | -689.76 | |||||
Net Margin % | -780.9 | |||||
EBITDA Margin % | -431.51 | |||||
FCF Margin % | -653.23 | |||||
OCF Margin % | -639.62 | |||||
ROA % | -128.78 | |||||
ROIC % | -461.29 | |||||
3-Year ROIIC % | 767.38 | |||||
ROC (Joel Greenblatt) % | -399.64 | |||||
ROCE % | -92.19 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.38 | |||||
EV-to-EBIT | 0.34 | |||||
EV-to-Forward-EBIT | 21.24 | |||||
EV-to-EBITDA | 0.35 | |||||
EV-to-Revenue | -1.52 | |||||
EV-to-Forward-Revenue | 0.39 | |||||
EV-to-FCF | 0.23 | |||||
Price-to-GF-Value | 0.04 | |||||
Earnings Yield (Greenblatt) % | 294.12 | |||||
FCF Yield % | -1668.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLSDQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clearside Biomedical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.329 | ||
| EPS (TTM) ($) | -5.19 | ||
| Beta | 2.6091 | ||
| 3-Year Sharpe Ratio | -0.85 | ||
| 3-Year Sortino Ratio | -0.99 | ||
| Volatility % | 144.68 | ||
| 14-Day RSI | 56.52 | ||
| 14-Day ATR ($) | 0.016291 | ||
| 20-Day SMA ($) | 0.236795 | ||
| 12-1 Month Momentum % | -98.08 | ||
| 52-Week Range ($) | 0.01 - 7.094849 | ||
| Shares Outstanding (Mil) | 5.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clearside Biomedical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clearside Biomedical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 104 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 6 days | ||
| General meeting for 2026 | 2026-07-31 08:00 | 0.25 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-07-31 | 0.25 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-07-31 | 0.25 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 3.69 (-2.12%) | ||
| 0.0666667:1 Stock Split | 2025-09-15 | 4.79 (-6.03%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 5.75 (-6.56%) | ||
| General meeting for 2025 | 2025-05-30 08:00 | 11.70 (-0.13%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 13.50 (-1.12%) |
Show
Entries
Clearside Biomedical Inc Frequently Asked Questions
What is Clearside Biomedical Inc(CLSDQ)'s stock price today?
The current price of CLSDQ is $0.25. The 52 week high of CLSDQ is $7.09 and 52 week low is $0.01.
When is next earnings date of Clearside Biomedical Inc(CLSDQ)?
The next earnings date of Clearside Biomedical Inc(CLSDQ) is 2026-07-31 Est..
Does Clearside Biomedical Inc(CLSDQ) pay dividends? If so, how much?
Clearside Biomedical Inc(CLSDQ) does not pay dividend.
Guru Commentaries on OTCPK:CLSDQ
No articles.
Press Release
Articles on Clearside Biomedical Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers